Immunotherapy and chemotherapy before radiation for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether giving an immunotherapy drug (PD-1 inhibitor) before and during standard chemotherapy and radiation can improve outcomes for people with advanced, HPV-negative head and neck cancer that cannot be removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HPV-negative head and neck cancer (in the voice box, throat, or mouth area).
- Your cancer is locally advanced (stage III or IVB).
- A team of doctors has confirmed that surgery is not an option for you, but you can have chemotherapy and radiation together.
- You are in good physical condition (able to care for yourself, up and about).
- Your blood counts and liver/kidney function are within certain limits.
- You have not had prior radiation, chemo, or immunotherapy for this cancer.
- You agree to use contraception during the study and for 8 weeks after.
- You are willing and able to follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests giving a short course of targeted radiation (SBRT) along with immunotherapy and a targeted drug before surgery for advanced head and neck cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a personalized radiotherapy approach after a few rounds of chemo-immunotherapy for people with HPV-negative head and neck cancer. It aims to adjust the radiation dose based on how the tumor responds, possibly reducing side effects while still controlling the cancer.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests a combination of low-dose radiation and an immunotherapy drug (similar to Keytruda) given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This Phase 2 study tests whether giving low-dose radiation before surgery—along with chemotherapy and an immunotherapy drug—can work better and be safe for treating locally advanced head and neck squamous cell cancer. It may help shrink tumors before surgery and reduce the chance of the cancer coming back.
Hear when a new HPV-unrelated Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.